Activity Description
This course provides a crucial update on the current clinical imperative to diagnose and intervene earlier in dry Age-Related Macular Degeneration (AMD) and Geographic Atrophy (GA). The session will begin by equipping attendees to identify key risk factors, biomarkers, and screening protocols used to diagnose these conditions, and interpret real-world evidence to support timely intervention and preserve vision.
We will then move into practical application, focusing on how to apply multimodal diagnostic and imaging strategies, including emerging AI applications, to monitor disease progression and identify patients at greatest risk for rapid progression to GA. Finally, the course will evaluate the clinical impact of GA on functional and anatomical outcomes, review patient communication strategies to improve compliance, and summarize the current and emerging pharmacologic therapies (including their mechanisms of action and safety/efficacy data) to help clinicians develop appropriate, real-world treatment protocols.
The Fundingsland Group is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Fundingsland Group, LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: 02-27-2026
Expiration Date: 02-27-2027
Target Audience
This accredited educational activity is designed for ophthalmologists.
Grant Support Statement
This activity is supported by unrestricted educational grants from Apellis Pharmaceuticals and Carl Zeiss Meditec.
Faculty
